Credit Agricole’s Lineage Cell Therapeutics LCTX Stock Holding History

Credit Agricole’s Portfolio LCTX Stock Details LCTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-58	Closed	–	–	706
2021 Q2	$0	Hold	58	–	–	﹤0.01%	711
2021 Q1	$0	Buy	+58	New	+$139	﹤0.01%	669

Other funds holding LCTX

Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

PGP

Prescott General Partners Boca Raton, Florida $1.37B AUM 23.81% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Credit Agricole's LCTX Position: Q3 2021 in Review

Credit Agricole sold out of Lineage Cell Therapeutics (LCTX) in Q3 2021, closing a stake of 58 shares.

Credit Agricole first reported a position in LCTX in Q1 2021 and held it in 2 quarters. The position peaked at $0 in Q2 2021. 115 funds tracked by Wall St. Rank hold LCTX as of Q3 2021.

Credit Agricole reported no remaining Lineage Cell Therapeutics position as of Q3 2021 after selling out during the quarter.
Credit Agricole sold 58 Lineage Cell Therapeutics shares in Q3 2021.
Credit Agricole first reported a position in Lineage Cell Therapeutics in Q1 2021 and held it in 2 quarters.
Credit Agricole's Lineage Cell Therapeutics position peaked at $0 in Q2 2021.
115 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q3 2021.

Based on Credit Agricole's 13F filing for Q3 2021, filed 15 Nov 2021.